01/28/2021
Message body: I have already done genetic studies on your tumor and I will look into germline testing next week.
Your PSA remains undetectable PSA <0.1 01/21/2021
PSA <0.1 12/22/2020
PSA <0.1 10/30/2020
The specimen met all input requirements.
The sequencing data passed all quality control assessments.
See Note.
Genomic Findings Associated Therapies
KRAS p.Q61H
NM_033360.3:c.183A>T
Estimated variant allele frequency: 17%
Standard of care biomarkers with no reportable alterations: N/A
Not eligible for NCI-MATCH - Exclusionary alteration present
Not eligible for Strata Trials - Exclusionary alteration present
Biomarker Findings Associated Therapies
MSS
Microsatellite Stable
Sequencing quality was insufficient for TMB assessment
1/2/L denotes line of therapy (first, second, later) indicated per FDA-approved drug label or recommended per NCCN guideline
for patient's tumor type. * indicates preferred therapy, ^ indicates emerging evidence, M indicates maintenance per NCCN
guideline. NCI-MATCH and Strata Trial Match indicate therapies available through partnered clinical trials.
Note
The tumor content was less than 40%, precluding detection of deep deletions.
Physician Information Specimen Information
Client Kaiser Permanente Sherman Way Histology Date of Collection 02/12/2018
Ordering Physician AMINU BIRHAN Date Received 12/11/2020